drugset / Trial / NCT06544330
A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1 study of SYNCAR-001 + STK-009 in patients with severe, refractory systemic autoimmune rheumatic disease.
Timeline
- Start
- 2025-04-29
- Primary completion
- 2028-04
- Completion
- 2041-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | STK-009 | Protein / enzyme biologic | — | Subcutaneous |
| Subject | SYNCAR-001 | Cell therapy | — | Intravenous |